A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Inclusion Criteria:

Phase I:

• Participant must be 18 to 55 years of age (inclusive), at the time of signing theinformed consent.

• Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within therange ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.

• Healthy participants with no clinically significant concomitant diseases ormedications (except for those specifically permitted by the protocol) according tomedical history, physical examination, screening safety laboratory tests, andscreening parameters, as perthe judgement of the investigator.

Phase IIa:

• Participant must be ≥ 18 years of age at the time of signing the informed consent.

• Participants who meet all of the following disease status requirements:

1. Diagnosed with End-stage kidney disease (ESKD).

2. Requiring hemodialysis through a tunneled central venous catheter as theprimary vascular access for hemodialysis.

3. Receiving hemodialysis for treatment of ESKD for at least 90 days beforerandomization.

4. At least 3 previous dialysis sessions using current dialyzer.

5. Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2within the last 30 days.

6. No new medications have been added to the participant's regimen in the last 2weeks prior to dosing. 'New medication' is defined as any medication that hasnot been prescribed or used by the participant previously (includingformulation changes). Medication previously prescribed or used by theparticipant with dose adjustments is allowed and not considered as newmedication for the purpose of this study.

7. Not taking long-term systemic antibiotics with activity against S aureus.

Exclusion Criteria:

Phase I:

• Known hypersensitivity to any component of the study intervention

• Previous hypersensitivity, infusion-related reaction, or severe adverse reactionfollowing administration of monoclonal antibodies (mAbs).

• Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, orplatelet disorder), or prior history of significant bleeding or bruising followingintramuscular injections or venipuncture.

• Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upperlimit of normal (ULN) at screening. Testing may be repeated once at theinvestigator's discretion.

• Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using theChronic Kidney Disease Epidemiology Collaboration equation at screening.

• Hemoglobin or platelet count below the lower limit of normal at screening. Testingmay be repeated once at the investigator's discretion.

• White blood cell counts outside normal reference ranges unless judged by theinvestigator to be out of range given the known variation in white blood cell countreference interval by ethnicity. Testing may be repeated once at the investigator'sdiscretion.

• History of malignancy other than treated non-melanoma skin cancers or locallytreated cervical cancer in the previous 5 years.

• Any laboratory value in the screening panel that, in the opinion of theinvestigator, is clinically significant or might confound analysis of study results.Testing may be repeated once at the investigator's discretion.

• Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) atscreening, as judged by the investigator.

• Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior toor on day of planned dosing; participants excluded for transient acute illness maybe dosed if illness resolves within the 28-day Screening Period or may be rescreenedonce.

• Known or suspected congenital or acquired immunodeficiency, or receipt ofimmunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other daywithin 6 months prior to screening.

• Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).

• Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reasonwithin 2 months prior to screening.

• Absence of suitable veins for blood sampling and administration of studyintervention.

• Any other condition that would compromise safety of the participants.

• Any condition that, in the opinion of the investigator, might interfere withevaluation of the study intervention or interpretation of participant safety orstudy results.

Phase IIa:

• Known hypersensitivity to any component of the study intervention.

• History of allergic disease or reactions likely to be exacerbated by any componentof the study intervention as listed in dose formulation section.

• Previous hypersensitivity, infusion-related reaction, or severe adverse reactionfollowing administration of mAbs.

• Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acutecondition(s). Testing may be repeated once at the investigator's discretion.

• Serum albumin of < 3 g/dL at screening considered by the investigator to be due toacute condition(s). Testing may be repeated once at the investigator's discretion.

• Myocardial infarction, acute coronary syndrome, stroke, seizure, or athrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, butexcluding vascular access thrombosis) within 90 days prior to randomization.

• Known S aureus infection within 90 days of study entry.

• Known acute viral or bacterial infection or symptoms/signs consistent with such aninfection within the 21 days prior to infusion or study intervention. Mildintercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does notrequire exclusion, if in the judgement of the investigator this illness will notinterfere with the evaluation of the mAb.

• Participants with malignancy undergoing chemotherapy.

• Scheduled date for living donor kidney transplant.

• Plans to switch to peritoneal dialysis within the primary endpoint time period (181days).

• Participants with a scheduled calendar date for transition to arteriovenous graft orarteriovenous graft in place and maturing.

• Participants with a scheduled calendar date for transition to arteriovenous fistula,or arteriovenous fistula in place and maturing, with anticipated use of fistulawithin 90 days.